Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A host cell transformed with a vector comprising a nucleic acid having at least 90% sequence identity to SEQ ID NO: 25 and a nucleic acid having at least 90% sequence identity to SEQ ID NO: 27.
2. The host cell of claim 1 , wherein the vector is a baculovirus vector.
3. A host cell transformed with a vector comprising a nucleic acid having at least 95% sequence identity to SEQ ID NO: 25 and a nucleic acid having at least 90% sequence identity to SEQ ID NO: 27.
4. The host cell of claim 3 , wherein the vector is a baculovirus vector.
5. A host cell transformed with a vector comprising a nucleic acid having at least 90% sequence identity to SEQ ID NO: 25 and a nucleic acid having at least 95% sequence identity to SEQ ID NO: 27.
6. The host cell of claim 5 , wherein the vector is a baculovirus vector.
7. A host cell transformed with a vector comprising a nucleic acid having at least 95% sequence identity to SEQ ID NO: 25 and a nucleic acid having at least 95% sequence identity to SEQ ID NO: 27.
8. The host cell of claim 7 , wherein the vector is a baculovirus vector.
9. A vaccine composition, comprising the transformed host cell of claim 1 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
10. A vaccine composition, comprising the transformed host cell of claim 2 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
11. A vaccine composition, comprising the transformed host cell of claim 3 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
12. A vaccine composition, comprising the transformed host cell of claim 4 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
13. A vaccine composition, comprising the transformed host cell of claim 5 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
14. A vaccine composition, comprising the transformed host cell of claim 6 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
15. A vaccine composition, comprising the transformed host cell of claim 7 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
16. A vaccine composition, comprising the transformed host cell of claim 8 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequences encode at least one immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
17. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 1 and a pharmaceutically or veterinarily acceptable carrier.
18. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 2 and a pharmaceutically or veterinarily acceptable carrier.
19. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 3 and a pharmaceutically or veterinarily acceptable carrier.
20. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 4 and a pharmaceutically or veterinarily acceptable carrier.
21. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 5 and a pharmaceutically or veterinarily acceptable carrier.
22. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 6 and a pharmaceutically or veterinarily acceptable carrier.
23. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 7 and a pharmaceutically or veterinarily acceptable carrier.
24. An immunogenic composition, comprising an immunizing amount of the transformed host cell of claim 8 and a pharmaceutically or veterinarily acceptable carrier.
25. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 9 .
26. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 10 .
27. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 11 .
28. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 12 .
29. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 13 .
30. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 14 .
31. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 15 .
32. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 16 .
33. A method of recovering proteins expressed by ORF′2 and ORF′3 from PCVB, said method including the steps a) infecting cells in growth media with a vector comprising a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:27; b) causing said vector to express said proteins; and c) recovering said expressed proteins.
34. The method of claim 33 , wherein the vector is a viral vector.
35. The method of claim 34 , wherein the vector is a baculovirus vector.
36. A method of recovering proteins expressed by ORF′2 and ORF′3 from PCVB, said method including the steps a) infecting cells in growth media with a vector comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:27; b) causing said vector to express said proteins; and c) recovering said expressed proteins.
37. The method of claim 36 , wherein the vector is a viral vector.
38. The method of claim 37 , wherein the vector is a baculovirus vector.
39. A method of recovering proteins expressed by ORF′2 and ORF′3 from PCVB, said method including the steps a) infecting cells in growth media with a vector comprising a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:27; b) causing said vector to express said proteins; and c) recovering said expressed proteins.
40. The method of claim 39 , wherein the vector is a viral vector.
41. The method of claim 40 , wherein the vector is a baculovirus vector.
42. A method of recovering proteins expressed by ORF′2 and ORF′3 from PCVB, said method including the steps a) infecting cells in growth media with a vector comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:27; b) causing said vector to express said proteins; and c) recovering said expressed proteins.
43. The method of claim 42 , wherein the vector is a viral vector.
44. The method of claim 43 , wherein the vector is a baculovirus vector.
45. A method of preparing a composition for inducing an immune response against PCVB, said method comprising the steps of: a) transferring a recombinant DNA comprising a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 into a virus; b) infecting cells with said virus, said cells being in a growth media; c) causing said virus to express the proteins encoded by said nucleic acid sequences; d) recovering said recombinant proteins; and e) combining said recovered proteins with a suitable adjuvant or other pharmaceutically acceptable carrier or excipient.
46. The method of claim 45 , wherein said method further including the step of obtaining said DNA from a transfer vector.
47. The method of claim 45 , said method further including the step of amplifying said nucleic acid from a strain of PCVB prior to cloning said nucleic acid into said transfer vector.
48. The method of claim 45 , said PCVB nucleic acids comprising SEQ ID NO:25 and SEQ ID NO:27.
49. The method of claim 45 , said cells comprising SF+ cells.
50. The method of claim 45 , said virus comprising baculovirus.
51. A method of preparing a composition for inducing an immune response against PCVB, said method comprising the steps of: a) transferring a recombinant DNA comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 into a virus; b) infecting cells with said virus, said cells being in a growth media; c) causing said virus to express the proteins encoded by said nucleic acid sequences; d) recovering said recombinant proteins; and e) combining said recovered proteins with a suitable adjuvant or other pharmaceutically acceptable carrier or excipient.
52. The method of claim 51 , wherein said method further including the step of obtaining said DNA from a transfer vector.
53. The method of claim 51 , said method further including the step of amplifying said nucleic acid from a strain of PCVB prior to cloning said nucleic acid into said transfer vector.
54. The method of claim 51 , said PCVB nucleic acids comprising SEQ ID NO:25 and SEQ ID NO:27.
55. The method of claim 51 , said cells comprising SF+ cells.
56. The method of claim 51 , said virus comprising baculovirus.
57. A method of preparing a composition for inducing an immune response against PCVB, said method comprising the steps of: a) transferring a recombinant DNA comprising a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:27 into a virus; b) infecting cells with said virus, said cells being in a growth media; c) causing said virus to express the proteins encoded by said nucleic acid sequences; d) recovering said recombinant proteins; and e) combining said recovered proteins with a suitable adjuvant or other pharmaceutically acceptable carrier or excipient.
58. The method of claim 57 , wherein said method further including the step of obtaining said DNA from a transfer vector.
59. The method of claim 57 , said method further including the step of amplifying said nucleic acid from a strain of PCVB prior to cloning said nucleic acid into said transfer vector.
60. The method of claim 57 , said PCVB nucleic acids comprising SEQ ID NO:25 and SEQ ID NO:27.
61. The method of claim 57 , said cells comprising SF+ cells.
62. The method of claim 57 , said virus comprising baculovirus.
63. A method of preparing a composition for inducing an immune response against PCVB, said method comprising the steps of: a) transferring a recombinant DNA comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:27 into a virus; b) infecting cells with said virus, said cells being in a growth media; c) causing said virus to express the proteins encoded by said nucleic acid sequences; d) recovering said recombinant proteins; and e) combining said recovered proteins with a suitable adjuvant or other pharmaceutically acceptable carrier or excipient.
64. The method of claim 63 , wherein said method further includes the step of obtaining said DNA from a transfer vector.
65. The method of claim 63 , said method further including the step of amplifying said nucleic acid from a strain of PCVB prior to cloning said nucleic acid into said transfer vector.
66. The method of claim 63 , said PCVB nucleic acids comprising SEQ ID NO:25 and SEQ ID NO:27.
67. The method of claim 63 , said cells comprising SF+ cells.
68. The method of claim 63 , said virus comprising baculovirus.
69. A polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:27.
70. A polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:28.
71. A polypeptide encoded by a nucleic acid having at least 95% identity to SEQ ID NO:27.
72. A polypeptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO:28.
73. A composition comprising a polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:25 and a polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:27.
74. A composition comprising a polypeptide encoded by a nucleic acid having at least 95% identity to SEQ ID NO:25 and a polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:27.
75. A composition comprising a polypeptide encoded by a nucleic acid having at least 90% identity to SEQ ID NO:25 and a polypeptide encoded by a nucleic acid having at least 95% identity to SEQ ID NO:27.
76. A composition comprising a polypeptide encoded by a nucleic acid having at least 95% identity to SEQ ID NO:25 and a polypeptide encoded by a nucleic acid having at least 95% identity to SEQ ID NO:27.
77. A composition comprising a polypeptide having at least 90% identity to SEQ ID NO:26 and a polypeptide having at least 90% identity to SEQ ID NO:28.
78. A composition comprising a polypeptide having at least 95% identity to SEQ ID NO:26 and a polypeptide having at least 90% identity to SEQ ID NO:28.
79. A composition comprising a polypeptide having at least 90% identity to SEQ ID NO:26 and a polypeptide having at least 95% identity to SEQ ID NO:28.
80. A composition comprising a polypeptide having at least 95% identity to SEQ ID NO:26 and a polypeptide having at least 95% identity to SEQ ID NO:28.
81. A vaccine comprising the polypeptides of claim 77 and a pharmaceutically or veterinarily acceptable carrier.
82. A vaccine comprising the polypeptides of claim 78 and a pharmaceutically or veterinarily acceptable carrier.
83. A vaccine comprising the polypeptides of claim 79 and a pharmaceutically or veterinarily acceptable carrier.
84. A vaccine comprising the polypeptide of claim 80 and a pharmaceutically or veterinarily acceptable carrier.
85. An immunogenic composition comprising the polypeptides of claim 77 and a pharmaceutically or veterinarily acceptable carrier.
86. An immunogenic composition comprising the polypeptides of claim 78 and a pharmaceutically or veterinarily acceptable carrier.
87. An immunogenic composition comprising the polypeptides of claim 79 and a pharmaceutically or veterinarily acceptable carrier.
88. An immunogenic composition comprising the polypeptides of claim 80 and a pharmaceutically or veterinarily acceptable carrier.
89. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 81 .
90. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 82 .
91. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 83 .
92. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 84 .
93. A diagnostic kit comprising the polypeptide of claim 69 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
94. A diagnostic kit comprising the polypeptide of claim 70 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
95. A diagnostic kit comprising the polypeptide of claim 71 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
96. A diagnostic kit comprising the polypeptide of claim 72 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
97. A diagnostic kit comprising the polypeptides of claim 73 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
98. A diagnostic kit comprising the polypeptides of claim 74 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
99. A diagnostic kit comprising the polypeptides of claim 75 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
100. A diagnostic kit comprising the polypeptides of claim 76 for detecting porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA).
101. A method for detecting and quantifying polypeptides of a porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA) method, wherein the polypeptides are encoded by a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:27.
102. A method for detecting and quantifying polypeptides of a porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA) method, wherein the polypeptides are encoded by a nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:27.
103. A method for detecting and quantifying polypeptides of a porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA) method, wherein the polypeptides are encoded by a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID NO:25 and a nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:27.
104. A method for detecting and quantifying polypeptides of a porcine circovirus type B (PCVB) by an Enzyme-Linked Immunosorbent Assay (ELISA) method, wherein the polypeptides are encoded by a nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:25 and a nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID NO:27.